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The ability to diagnose patients with developmental
delay, intellectual disability, congenital anomalies, and
dysmorphic features has significantly improved with the
introduction of SNP microarray technologies which
includes more than 1.8 million markers on a single
array. This high-density array will allow for sensitively
detecting all known abnormalities with defined loci of
interest as well as the discovery of ‘‘new syndromes’’ as
a cause of mental retardation or autism. The most
common micro deletion disorders include15q11-q13
Prader-Willi/Angelman, 22q11.3 velo-cardiofacial,
17pl3.3 William, 1p36and 16p11.2 microdeletion syn-
dromes. SNP arrays are able to detect segmental uniparen-
tal disomy (UPD) as in Prader Willi syndrome and
UPD14. SNP arrays identify parental consanguinity which
may otherwise go undetected. Long stretches of homozyg-
osity can be analyzed for recessive genes in patients born
to consanguineous parents. (http://www.ccs.miami.edu/
cgi-bin/ROH/ROH_analysis_tool.cgi)
Arrays cannot however identify balanced chromosomal
rearrangements, such as translocations or inversions,
Marker chromosomes may also be missed, depending on
the size, marker composition, and array coverage of the
specific chromosomal region present on the marker.
Dilemmas arise when ‘‘CNVs of uncertain clinical signifi-
cance’’ are identified, or if a parent is not available for
testing, thus making it difficult to identify if the rearran-
gement is inherited or arose de-novo. Further dilemmas
arise if a parent is identified with the same rearrangement
and is apparently asymptomatic, should one then con-
sider the presence of a mutation in a recessive gene in
the other allele to explain autism, mental retardation or
other disorders.
Overall SNP array technology has become the test of
choice, permitting a 5.9% detection rate in patients with
negative microarray-based CGH and an overall detection
rate approaching 29%.
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